Předmět: |
|
Zdroj: |
Immunotherapy Weekly; 9/17/2024, p2487-2487, 1p |
Abstrakt: |
A recent study conducted by researchers at Case Western Reserve University has found that nanoparticles targeting the immune checkpoint protein VISTA can induce potent antitumor immunity. The researchers developed a dual-action lipid nanoparticle (dual-LNP) that co-loaded VISTA-specific siRNA and a TLR9 agonist CpG oligonucleotide. In preclinical tumor models, the dual-LNP demonstrated superior therapeutic efficacy compared to other treatments, resulting in a high cure rate and tumor rejection. The study suggests that the dual-LNP may be a promising therapeutic platform for treating immune-cold tumors. [Extracted from the article] |
Databáze: |
Complementary Index |
Externí odkaz: |
|